COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Xi urges deepening reform, opening-up during Guangdong inspection tour
- Xi attends carrier's commissioning
- Xi inspects Meizhou in South China's Guangdong
- Senior Xi'an official facing probe by China's anti-corruption watchdogs
- Philippines risks creating trouble for itself: China's defense ministry
- Newborn with congenital heart disease receives life-saving surgery in Yunnan
